Señales en vivo de SPL.AX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 01:42):

Stats
Volumen de hoy	76 190.00
Volumen promedio	382 721
Capitalización de mercado	51.51M
EPS	$0 ( 2024-02-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.25
ATR14	$0.00100 (0.80%)

Volumen Correlación

Largo: -0.15 (neutral)

Corto: -0.72 (moderate negative)

Signal:(55.704) Neutral

Starpharma Holdings Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Starpharma Holdings Ltd Correlación - Moneda/Commodity

0.00
( neutral )

0.27
( neutral )

0.00
( neutral )

0.36
( neutral )

Starpharma Holdings Ltd Finanzas

Annual	2023
Ingresos:	$2.94M
Beneficio Bruto:	$1.22M (41.60 %)
EPS:	$-0.0400

FY	2023
Ingresos:	$2.94M
Beneficio Bruto:	$1.22M (41.60 %)
EPS:	$-0.0400

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$0

FY	2022
Ingresos:	$4.68M
Beneficio Bruto:	$1.91M (40.71 %)
EPS:	$-0.0400

Financial Reports:

No articles found.

Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.